Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Medical Oncology Physician in Loma Linda, CA
NPI: 1073542692Primary Practice Location
LOMA LINDA UNIVERSITY MEDICAL CENTER
11234 Anderson St, Loma Linda, CA
Primary Employer
Faculty Physicians and Surgeons of Llusm
lluh.org
HQ Phone
Get M.D. Chien-Shing's Phone Numberphone_androidMobile
Get M.D. Chien-Shing's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1998 - 2025
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Medical Oncology
University of Washington
Fellowship • Hematology and Medical Oncology
1995 - 1998
Washington University/B-JH/SLCH Consortium
Residency • Internal Medicine
1993 - 1995
University of Minnesota
Ph.D. • Molecular Oncology/Pathobiology
1988 - 1992
China Medical University (Taiwan)
Medical School
Until 1985
University Of Washington School Of Medicine
uwmedicine.washington.edu
Fellowship • Oncology/Bmt
1995 - 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 73 | 152 |
| 2 | 99212Established patient outpatient visit, total time 10-19 minutes | 58 | 85 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 50 | 62 |
| 4 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 32 | 41 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?
AML sensitivity to YM155 is modulated through AKT and Mcl-1.
Authors: de Necochea-Campion, Rosalia, Diaz Osterman, Carlos J, Hsu, Heng-Wei, Fan, Junjie, Mirshahidi, Saied, Wall, Nathan R, Chen, Chien-Shing
Journal: Cancer Lett
Publication Date: 2015-06-25
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Biospecimen Collection, DRUG: Prednisone, DRUG: Vincristine Sulfate, DRUG: Methotrexate, PROCEDURE: Computed Tomography, PROCEDURE: X-Ray Imaging, DRUG: Vincristine, DRUG: Dasatinib, BIOLOGICAL: Blinatumomab, DRUG: Mercaptopurine, PROCEDURE: Biopsy Procedure, PROCEDURE: Echocardiography Test, PROCEDURE: Bone Marrow Aspiration and Biopsy, PROCEDURE: Lumbar Puncture, DRUG: Methotrexate Sodium
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Temozolomide, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging, DEVICE: NovoTTF-100A Device
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Pharmacological Study, PROCEDURE: Biospecimen Collection, OTHER: Clinical Observation, OTHER: Quality-of-Life Assessment, PROCEDURE: Computed Tomography, PROCEDURE: Cystoscopy, PROCEDURE: CT Urography
